GlassScriptPhysician profile
Parisha P Shah
NPI 1962767525
$2,781.97
in general payments reported to CMS, 2019-2025
25 companies · $565 in 2025
The $565 reported for 2025 was more than what 80% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $524 · 2020: $134 · 2021: $210 · 2022: $746 · 2023: $150 · 2024: $454 · 2025: $565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,168.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $373.72 | 2019-2023 | Tobradex St |
| Notal Vision, INC. | $325.03 | 2022 | |
| Novartis Pharmaceuticals Corporation | $277.32 | 2020-2023 | |
| Abbvie INC. | $240.71 | 2022-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $216.00 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $170.19 | 2019-2025 | |
| Harrow Eye, LLC | $158.24 | 2024-2025 | Vevye |
| Bausch & Lomb Americas INC. | $141.01 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Biotissue Holdings INC. | $133.57 | 2021-2025 | |
| Tarsus Pharmaceuticals, INC. | $118.82 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $93.69 | 2022-2025 | Tryptyr, Rocklatan |
| Johnson & Johnson Surgical Vision, INC. | $73.38 | 2021-2024 | Tecnis Iol |
| Astellas Pharma US INC | $64.71 | 2024 | Izervay |
| Shire North American Group INC | $49.98 | 2019 | |
| Amgen INC. | $48.11 | 2025 | Tepezza |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $44.44 | 2022-2024 | Tyrvaya |
| Dompe US, INC. | $41.13 | 2025 | Oxervate |
| Horizon Therapeutics Plc | $40.07 | 2022 | |
| Abb Con-Cise Optical Group LLC | $39.11 | 2024 | Spectacle Lenses, Contact Lens |
| Rayner Intraocular Lenses Limited | $36.82 | 2024 | Omidria |
| Tearlab Corp | $24.84 | 2024 | Scoutpro Osmolarity System |
| Sight Sciences, INC. | $21.51 | 2025 | Tearcare System |
| Apellis Pharmaceuticals, INC. | $19.36 | 2025 | Syfovre |
| Spark Therapeutics, INC. | $18.10 | 2020 | |
| Vantage Technology LLC | $12.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parisha Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.